Logo image of CACO

CARAVELLE INTERNATIONAL GROU (CACO) Stock Fundamental Analysis

NASDAQ:CACO - Nasdaq - KYG1901X1088 - Common Stock - Currency: USD

0.4401  -0.02 (-3.78%)

After market: 0.4621 +0.02 (+5%)

Fundamental Rating

2

Overall CACO gets a fundamental rating of 2 out of 10. We evaluated CACO against 31 industry peers in the Marine Transportation industry. The financial health of CACO is average, but there are quite some concerns on its profitability. CACO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CACO has reported negative net income.
In the past year CACO has reported a negative cash flow from operations.
CACO Yearly Net Income VS EBIT VS OCF VS FCFCACO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 -100K -200K -300K

1.2 Ratios

CACO's Return On Assets of -1.27% is on the low side compared to the rest of the industry. CACO is outperformed by 85.19% of its industry peers.
With a Return On Equity value of -1.33%, CACO is not doing good in the industry: 81.48% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -1.27%
ROE -1.33%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CACO Yearly ROA, ROE, ROICCACO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 -0.1 -0.2 -0.3

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CACO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CACO Yearly Profit, Operating, Gross MarginsCACO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, CACO has about the same amount of shares outstanding.
CACO has about the same debt/assets ratio as last year.
CACO Yearly Shares OutstandingCACO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2M 4M 6M
CACO Yearly Total Debt VS Total AssetsCACO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

CACO has an Altman-Z score of 6.94. This indicates that CACO is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 6.94, CACO belongs to the best of the industry, outperforming 96.30% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that CACO is not too dependend on debt financing.
CACO has a better Debt to Equity ratio (0.00) than 88.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.94
ROIC/WACCN/A
WACCN/A
CACO Yearly LT Debt VS Equity VS FCFCACO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 0 10M 20M 30M 40M 50M

2.3 Liquidity

CACO has a Current Ratio of 23.07. This indicates that CACO is financially healthy and has no problem in meeting its short term obligations.
CACO has a better Current ratio (23.07) than 96.30% of its industry peers.
CACO has a Quick Ratio of 23.07. This indicates that CACO is financially healthy and has no problem in meeting its short term obligations.
CACO has a better Quick ratio (23.07) than 96.30% of its industry peers.
Industry RankSector Rank
Current Ratio 23.07
Quick Ratio 23.07
CACO Yearly Current Assets VS Current LiabilitesCACO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CACO have decreased by 0.00% in the last year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-405.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CACO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CACO Price Earnings VS Forward Price EarningsCACO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CACO Per share dataCACO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CACO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARAVELLE INTERNATIONAL GROU

NASDAQ:CACO (9/27/2024, 8:00:02 PM)

After market: 0.4621 +0.02 (+5%)

0.4401

-0.02 (-3.78%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryMarine Transportation
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.39%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap24.69M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.32
Dividend Growth(5Y)N/A
DP-2283.87%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.44
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS1
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.27%
ROE -1.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.07
Quick Ratio 23.07
Altman-Z 6.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-405.63%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0%
OCF growth 3YN/A
OCF growth 5YN/A